Please login to the form below
AZD3293
This page shows the latest AZD3293 news and features for those working in and with pharma, biotech and healthcare.
Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat
The demise of the BACE1 inhibitor – also known as AZD3293/LY3314814 – adds to the litany of failures among drugs intended to treat Alzheimer’s, and specifically those trying to slow down
Latest news
-
Biogen rises on more positive data for Alzheimer's candidate
compounds. . Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
-
Lilly taps AstraZeneca for another anti-amyloid drug
The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running
-
Lilly sinks as solanezumab fails again in Alzheimer's
AZD3293. Ricks has previously suggested that if EXPEDITION3 was a bust then the expensive, 2, 500-patient prodromal trial will probably be abandoned.
-
AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug
AMARANTH could be first treatment to target underlying mechanism. . AstraZeneca and Eli Lilly's collaboration in Alzheimer's disease continues to make progress, as their AZD3293 drug is granted a ... AZ and Lilly are already carrying out one phase
-
Eisai and Biogen plan phase III trials for Alzheimer's drug
others. Merck has already started phase III trials of its MK-8931 candidate, while Lilly and AZ recently did likewise with AZD3293.
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2016
Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Editorial Assistants - Medical Communications agency - Cheshire
-
Excellent Remuneration Package
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior / Principal Medical Writers wanted - MedComms - Various U...
-
Excellent Remuneration Packages
- Experienced / Senior Medical Writer - Excellent Progression Oppo...
-
Excellent Salary and Benefits on offer
- Senior Account Manager / Account Director - MedComms - London
-
Highly competitive salary &package
- Senior Medical Writer – Medical Communications – North West – In...
-
Excellent Remuneration Package
-
Senior Medical Writer
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
-
Senior Copywriter
-
Salary TBC
Subscribe to our email news alerts
- Leading AstraZeneca’s return to growth in Europe
- Eli Lilly shutters UK neuroscience unit, with 80 job losses expected
- Allergan investors back AbbVie deal, but is a tax charge looming?
- Roche reports continued growth in Q3, despite biosimilar competition
- Faisal Ahmed joins healthcare comms agency Sudler London
- Takeda offloads select portfolio to Acino ahead of Shire takeover
- The best in the UK healthcare system celebrated at QiC Diabetes awards 2019
- Merck wins CHMP recommendation for Ebola vaccine
- Roche scores another FDA approval for Xofluza
- CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal
- AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs
- A snapshot of Crescendo Biologics
PMHub
Complete Medical Communications (CMC)
CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...
Latest intelligence
- A snapshot of Crescendo Biologics
- PME talks to CEO Theodora Harold...
- eyeforpharma Marketing and Customer Innovation Europe
- By Richard Springham...
- The Golden Goose
- Why it’s so hard for the US to curb runaway drug prices...
Quick links
Infographics
